EGFR and non-small cell lung carcinoma: Additionally, NFKB signalling presented TKI resistance to EGFR-mutant NSCLC cells with smoking and never smoking history; however, inactivating NFKB using TLR-9 agonist along with erlotinib did not increase PFS in comparison to using erlotinib alone [41].